ENDRA Life Sciences Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-24.
ENDRA Life Sciences Inc. filed a Form D notice of an exempt securities offering with the SEC on October 24, 2025. The filing reports $14.40M sold. Its industry group is Biotechnology. It names Alexander Tokman (Executive Officer, Director), Michael Thornton (Executive Officer), Richard Jacroux (Executive Officer) (SEC Form D, October 24, 2025).
Is this your company?
Sell to companies like ENDRA Life Sciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ENDRA Life Sciences Inc.
Free to see. No signup.
More on the people and the money behind ENDRA Life Sciences Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when ENDRA Life Sciences Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ENDRA Life Sciences Inc. raises, hires or launches. No email unless you switch it on.
Watch ENDRA Life Sciences Inc. →Get the full cited report on ENDRA Life Sciences Inc.
What the filing shows about ENDRA Life Sciences Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ENDRA Life Sciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives ENDRA Life Sciences Inc.'s address as 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on ENDRA Life Sciences Inc. See pricing
ENDRA Life Sciences Inc. is a registered filer with the SEC (CIK 1681682) and has filed since 2025-10-24. 1 filing is on record, the latest on 2025-10-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
ENDRA Life Sciences Inc.'s Form D of 2025-10-24 names Alexander Tokman, Michael Thornton, Richard Jacroux and 3 more as its officers, directors or promoters.
Its new offerings report $14.40M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Alexander Tokman is named as Executive Officer and Director on the Form D that ENDRA Life Sciences Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Michael Thornton is named as Executive Officer on the Form D that ENDRA Life Sciences Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Richard Jacroux is named as Executive Officer on the Form D that ENDRA Life Sciences Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Louis Basenese is named as Director on the Form D that ENDRA Life Sciences Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Anthony DiGiandomenico is named as Director on the Form D that ENDRA Life Sciences Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
Michael Harsh is named as Director on the Form D that ENDRA Life Sciences Inc. filed with the SEC on 24 October 2025, one of 6 people that filing names.
6 people named on the filing — 3 holding an executive role and 3 as directors only.
Named as of the 2025-10-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ENDRA Life Sciences Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ENDRA Life Sciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ENDRA Life Sciences Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ENDRA Life Sciences Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind ENDRA Life Sciences Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ENDRA Life Sciences Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Detroit
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/endra-life-sciences-inc-form-d-25000001